Huw Morris leads the Cohort Integration working group (CIWG). In this blog post, Huw provides an outline of the research on Parkinson’s disease over the last 25 years and shares the plans of the CIWG to harmonize clinical data from research participants to enable large clinical outcomes research. The post Building Clinical and Genetic Data for GP2 in the Cohort Integration Working Group appeared first on Aligning Science Across Parkinson's.| Aligning Science Across Parkinson's
As a follow-up to the last blog post on Understanding GWAS, the GP2 Complex Disease Data Analysis Working Group has provided practical tips and insights for running your own GWAS. The post Understanding GWAS: Part 2 – Additional Insights and Tips appeared first on Aligning Science Across Parkinson's.| Aligning Science Across Parkinson's
Adding a layer of compute to connect two massive datasets is where we are headed. Mike Nalls, Hampton Leonard, Matt Bookman, and Eline Appelmans outline the partnership between The Global Parkinson’s Genetics Program (GP2) and Accelerating Medicines Partnership: Parkinson's Disease (AMP PD) to be your one-stop shop for PD genetic and genomic data in this new blog post. The post GP2 and AMP PD: Platform Partners for Progress in Parkinson’s Research appeared first on Aligning Science Across...| Aligning Science Across Parkinson's
Members of the GP2 Operations and Compliance working group provide an overview of what compliance is and why it is important in GP2. The post What is Compliance and Why is it Important? appeared first on Aligning Science Across Parkinson's.| Aligning Science Across Parkinson's
Members of the GP2 Complex Disease Data Analysis working group provide an overview of Genome-Wide Association Studies (GWAS), including statistical formulae, workflows, and examples from the most recent Parkinson’s disease GWAS. The post Understanding GWAS appeared first on Aligning Science Across Parkinson's.| Aligning Science Across Parkinson's
Christine Klein leads the GP2 Monogenic Hub. In this post Christine shares how her interest in Parkinson’s disease genetics was sparked, which genes have been discovered so far, and the questions which are still to be answered. The post Parkinson’s Disease Genetics: Cause, Risk, or Protection? appeared first on Aligning Science Across Parkinson's.| Aligning Science Across Parkinson's
GP2 aims to identify novel disease-causing genes and mutations. Benjamin Stecher outlines his hopes for GP2, as we delve into the unknown and build a foundation of knowledge from which new therapies may come. The post Decoding the Aliens Within appeared first on Aligning Science Across Parkinson's.| Aligning Science Across Parkinson's
In GP2, underlying data, analytical processes, and results will be made available to the research community as quickly as possible, with minimal barriers to access and use. The latest blog post by Bradford Casey highlights the value and importance of open science. The post Open Science Opens Doors appeared first on Aligning Science Across Parkinson's.| Aligning Science Across Parkinson's
ASAP Scientific Director, Randy Schekman, expresses his personal and professional connection with Parkinson's disease in a letter to the patient community, shared by patient advocate Benjamin Stecher.| Aligning Science Across Parkinson's
Training is a crucial element of GP2. In this blog post, Alastair Noyce, Sara Bandres-Ciga and Emily Fisher outline the program's training and development goals.| Aligning Science Across Parkinson's